Wednesday, February 05, 2025 12:51:52 PM
Crazy low floater with less than 696k outstanding shares and being shorted by muthafuckers because they want more cheap shares after the reverse split last year which current shareholders spoke loudly yesterday by denying them issuing more shares so close after the reverse split!!!!
FUCK 'EM WHERE THEY BREATHE!!!!
FUCK 'EM WHERE THEY BREATHE!!!!
Recent RNAZ News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:17:42 PM
- TransCode Therapeutics signs financing deal worth up to $20 million • IH Market News • 04/07/2026 01:51:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/07/2026 12:37:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:35:16 PM
- TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 • PR Newswire (US) • 04/07/2026 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/03/2026 09:06:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:05:39 PM
- TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Pa • PR Newswire (US) • 03/03/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:10:39 PM
- TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development • PR Newswire (US) • 02/23/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 01:10:42 PM
- TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 • PR Newswire (US) • 02/05/2026 01:04:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/07/2026 05:38:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 01:04:38 PM
- TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma • PR Newswire (US) • 01/06/2026 01:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/23/2025 09:17:28 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/23/2025 09:15:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2025 01:13:34 PM
- TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors • PR Newswire (US) • 12/22/2025 01:01:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/12/2025 09:17:03 PM
- TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial • PR Newswire (US) • 12/11/2025 01:05:00 PM
- TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer • PR Newswire (US) • 11/17/2025 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:03:02 PM
